Drug Profile
Ethinylestradiol/drospirenone
Alternative Names: Dihydrospirorenone/ethinylestradiol; Drospirenone/ethinylestradiol; Petibelle; SH 470; Yasmin; ZK 30595Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Class Alkylated estrogenic steroids; Androstenes; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pregnancy
- No development reported Acne; Premenstrual dysphoric disorder; Premenstrual syndrome
Most Recent Events
- 08 Sep 2015 Generic equivalent available in USA for Contraception
- 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Switzerland, Norway, Israel, China, Malaysia, Philippines, Singapore, Thailand, Indonesia, Hong Kong and South Africa (PO) prior to February 2015
- 11 Apr 2012 Bayer updated the labelling of ethinylestradiol/drospirenone regarding the risk of venous thromboembolism